Genzyme's Thymoglobulin receives FDA approval for additional manufacturing at Ireland plant

By Elaine Rigoli

Tampa, Fla., July 24 - Genzyme Corp. said the Food and Drug Administration has approved the fill/finishing, packaging and labeling of Thymoglobulin (anti-thymocyte globulin, rabbit) at its Waterford, Ireland, facility.

The approval allows Genzyme to begin manufacturing and distribution of Thymoglobulin, a product for the treatment of acute rejection in patients with a kidney transplant, from this single location.

Genzyme said that when the company completed a major expansion in Waterford last year, it added biological filling and packaging capabilities to support the growth of protein products such as Myozyme and Cerezyme, along with products like Thymoglobulin that are manufactured at other Genzyme facilities.

Genzyme is a biotechnology company based in Cambridge, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.